Document is current

Any future updates will be listed below

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for colorectal cancer, trastuzumab deruxtecan for breast cancer, and acalabrutinib for mantle cell lymphoma

Crossref DOI link: https://doi.org/10.1007/s10147-025-02879-y

Published Online: 2025-09-15

Published Print: 2025-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark